Agenus Inc. (AGEN) is advancing a phase III study called BATTMAN, targeting its combination therapy of botensilimab and balstilimab (BOT+BAL) for refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC). This condition has shown limited response to existing checkpoint inhibitors. The study aims to provide compelling evidence of efficacy in late-stage patients, especially given early signals showing a two-year overall survival rate of approximately 42% and a median overall survival near 21 months among heavily pretreated patients without active liver metastases.
The BATTMAN trial is crucial for Agenus as success could lead to significant regulatory filings and market opportunities. It involves a comprehensive evaluation of benefits across subgroups and will help determine the feasibility of commercial presence against established competitors like Merck’s Keytruda and Bristol Myers Squibb’s Opdivo/Yervoy. The trial’s results could potentially establish a new treatment standard in an area of high unmet need.
Additionally, Agenus has treated nearly 1,300 patients across various phases of study, indicating a solid platform for potential expansion into other difficult cancer types. However, the company faces challenges regarding funding, with a significant reliance on external capital posing risks to the timeline and success of its ongoing projects.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
